Russell Investments Group Ltd. boosted its stake in shares of Inari Medical, Inc. (NASDAQ:NARI – Get Rating) by 25.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,384 shares of the company’s stock after purchasing an additional 4,773 shares during the quarter. Russell Investments Group Ltd.’s holdings in Inari Medical were worth $1,486,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust bought a new position in Inari Medical during the first quarter worth $25,000. Hollencrest Capital Management acquired a new stake in shares of Inari Medical during the fourth quarter worth $25,000. Canada Pension Plan Investment Board lifted its holdings in shares of Inari Medical by 40.9% during the third quarter. Canada Pension Plan Investment Board now owns 689 shares of the company’s stock worth $50,000 after buying an additional 200 shares in the last quarter. FMR LLC lifted its holdings in shares of Inari Medical by 42.6% during the second quarter. FMR LLC now owns 824 shares of the company’s stock worth $56,000 after buying an additional 246 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Inari Medical by 38.8% during the third quarter. Nisa Investment Advisors LLC now owns 1,388 shares of the company’s stock worth $106,000 after buying an additional 388 shares in the last quarter. 85.19% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their target price on Inari Medical from $77.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, February 28th. Truist Financial boosted their price target on Inari Medical from $68.00 to $70.00 in a report on Tuesday, April 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.11.
Inari Medical Stock Performance
Inari Medical (NASDAQ:NARI – Get Rating) last issued its earnings results on Wednesday, May 3rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.19. Inari Medical had a negative return on equity of 6.78% and a negative net margin of 6.87%. The company had revenue of $116.17 million for the quarter, compared to analyst estimates of $110.30 million. During the same period in the prior year, the firm earned ($0.06) earnings per share. Inari Medical’s revenue for the quarter was up 33.9% on a year-over-year basis. Research analysts predict that Inari Medical, Inc. will post -0.29 EPS for the current fiscal year.
Insider Transactions at Inari Medical
In other news, insider Thomas Tu sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $56.72, for a total transaction of $567,200.00. Following the transaction, the insider now directly owns 107,112 shares of the company’s stock, valued at $6,075,392.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Thomas Tu sold 10,000 shares of the stock in a transaction on Monday, February 27th. The stock was sold at an average price of $56.72, for a total value of $567,200.00. Following the completion of the sale, the insider now directly owns 107,112 shares of the company’s stock, valued at approximately $6,075,392.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director William Hoffman sold 41,891 shares of the stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $69.19, for a total value of $2,898,438.29. Following the completion of the sale, the director now directly owns 1,120,643 shares of the company’s stock, valued at $77,537,289.17. The disclosure for this sale can be found here. Insiders have sold 184,233 shares of company stock valued at $12,319,658 over the last ninety days. 13.70% of the stock is owned by company insiders.
Inari Medical Profile
Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.
- Get a free copy of the StockNews.com research report on Inari Medical (NARI)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. (NASDAQ:NARI – Get Rating).
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.